Identifying and eliminating the roadblocks to comparative-effectiveness research.
Martin
Daniel F
DF
Cole Eye Institute, Cleveland Clinic, Cleveland, USA.
Maguire
Maureen G
MG
Fine
Stuart L
SL
D057171:American Recovery and Reinvestment Act; D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic / Q000191:economics; D057186:Comparative Effectiveness Research / Q000191:economics* / Q000458:organization & administration; D016527:Drug Costs; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D006278:Medicare / Q000191:economics*; D000069579:Ranibizumab; D014481:United States
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab